Subscribe to Cephalon

The Lead

California Counties Sue Over Painkiller Marketing

May 22, 2014 3:18 pm | by PAUL ELIAS, Associated Press | News | Comments

Two California counties have filed a lawsuit accusing five drug companies of waging a campaign of deception to boost the sales of painkillers behind the nation's prescription drug addiction problem.         

South Carolina's Suit to Recover Millions From Cephalon to Move Forward

March 10, 2014 8:12 am | News | Comments

The South Carolina Court of Common Pleas, Fifth Judicial Circuit has issued a ruling that will...

Mylan Launches Generic Version of Provigil Tablets

August 10, 2012 4:01 am | News | Comments

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval...

Mylan Sues FDA Seeking Ruling That Teva Holds No Exclusivity for Its Generic Version of Provigil

April 6, 2012 4:15 am | News | Comments

Mylan Inc. today announced that its subsidiary, Mylan Pharmaceuticals Inc., has filed suit against...

View Sample

FREE Email Newsletter

Teva Set to Complete Purchase of Cephalon

October 14, 2011 4:57 am | by Matthew Dennis | News | Comments

Teva announced that it has now received all regulatory approvals required to complete its planned purchase of Cephalon after the European Commission cleared the transaction.

FTC Requests Additional Info Regarding Teva’s Acquisition of Cephalon

June 14, 2011 5:14 am | News | Comments

Teva Pharmaceutical Industries Ltd. and Cephalon, Inc. announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal Trade Commission (FTC) in connection with Teva's pending acquisition of Cephalon.

Teva Buying Cephalon for $6.8B

May 2, 2011 4:55 am | News | Comments

NEW YORK (AP) — Teva Pharmaceutical Industries Ltd. has agreed to buy Cephalon Inc. for $6.8 billion in a deal that would give the world's largest generic drug developer a range of biotechnology drugs aimed at cancer and other conditions


Cephalon Makes Bid for ChemGenex Pharmaceuticals

April 13, 2011 7:36 am | News | Comments

Cephalon, Inc. has announced that its wholly-owned subsidiary, Cephalon CXS Holdings Pty Ltd (Cephalon), has lodged the offer document (Bidder's Statement) for its A$0.70 a share offer for ChemGenex Pharmaceuticals Limited (ASX: CXS) (ChemGenex) with the Australian Securities and Investments Commission.

Cephalon Rejects Takeover Bid from Valeant

April 6, 2011 4:43 am | News | Comments

Cephalon Inc.'s shares fell slightly in pre-market trading a day after the U.S. drug company formally rejected a hostile takeover bid by Canada's Valeant Pharmaceuticals International.

Cephalon Wins FENTORA Patent Suit Against Watson

March 25, 2011 4:37 am | News | Comments

Cephalon, Inc. announced that today the United States District Court in Delaware upheld the validity of Cephalon's U.S. Patent Number 6,264,981 patent and found that Watson Pharmaceuticals, Inc.'s proposed generic version of FENTORA® (fentanyl buccal tablet) infringes that patent.

Cephalon to Acquire Gemin X

March 22, 2011 4:28 am | News | Comments

Cephalon, Inc. has signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, for $225 million cash on a cash-free, debt-free basis.

Court Rules Against Cephalon

March 14, 2011 4:54 am | News | Comments

NEW YORK (AP) — A federal court overturned two of the patents on Cephalon Inc.'s painkiller Fentora, according to Cephalon and Watson Pharmaceuticals Inc., which is challenging the patents.


Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics

February 10, 2011 3:29 am | News | Comments

Cephalon, Inc. and Alba Therapeutics Corporation, a privately held biopharmaceutical company, today announced that the companies have signed an agreement providing Cephalon with an option to purchase all of Alba's assets relating to larazotide acetate, a tight junction modulator, progressing toward a Phase IIb clinical trial for the treatment of celiac disease.

Cephalon Appoints New CEO

December 23, 2010 3:36 am | News | Comments

Cephalon, Inc. announced today that its Board of Directors has appointed J. Kevin Buchi as Chief Executive Officer and a member of the company's Board. The Board will address the role of company Chairman in the future. William P. Egan will continue to serve as Cephalon's independent Presiding Director.

Judge Recommends Watson CEO Testify in FTC Probe

August 20, 2010 4:29 am | News | Comments

NEW YORK (AP) — A federal judge has recommended Watson Pharmaceuticals CEO Paul Bisaro testify in a federal investigation into the generic drug developer's patent settlement with biotechnology company Cephalon.

Cephalon Receives Complete Response Letter for NUVIGIL

March 30, 2010 4:54 am | News | Comments

Cephalon, Inc. has received a Complete Response letter from the FDA for its supplemental new drug application for NUVIGIL® (armodafinil) Tablets [C-IV] in the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel.

Cephalon Exercises its Option to Acquire Ception Therapeutics

February 23, 2010 5:47 am | News | Comments

Cephalon, Inc. announced today that it has exercised its option to acquire Ception Therapeutics, Inc., following receipt of positive data from a clinical study in adults with eosinophilic asthma.


Cephalon Fourth Quarter Profit Jumps on Sales, Lower Charges

February 12, 2010 9:46 am | News | Comments

FRAZER, Pa. (AP) — Biotechnology company Cephalon Inc. said Thursday its fourth-quarter profit surged on a boost in sales and lower charges.

BioClinica Inks Multi-Year Outsourcing Deal with Leading Biopharmaceutical Company

February 5, 2010 9:51 am | News | Comments

BioClinica, Inc., a global provider of clinical trial services, has signed a three-year, multi-million dollar deal with Cephalon, Inc. for clinical trial technology and support services.

Cephalon Announces Executive Leadership Changes

January 28, 2010 8:45 am | News | Comments

Cephalon, Inc., has announced the promotion of three executives, Kevin Buchi, Wilco Groenhuysen and Alain Aragues.

FDA Letters Cite Lilly, Bayer, Amylin and Cephalon

January 13, 2010 4:15 am | News | Comments

MATTHEW PERRONE AP Business Writer WASHINGTON (AP) — Federal health regulators have issued enforcement letters to Eli Lilly, Bayer, Amylin Pharmaceuticals and Cephalon for making inaccurate or incomplete statements while promoting their drugs.

Mylan Confirms First-to-File Patent Challenge Relating to Sleep-Disorder Drug Nuvigil(R)

January 11, 2010 4:21 am | News | Comments

Mylan confirmed that it was sued by Cephalon Inc. and Cephalon France inconnection with the filing of an Abbreviated New Drug Application (ANDA) withthe U.S. Food and Drug Administration (FDA) for Armodafinil Tablets, 50 mg,150 mg and 250 mg.

Cephalon Executive Vice President of Worldwide Pharmaceutical OperationsRobert Roche to Resign Position

January 8, 2010 4:27 am | News | Comments

Cephalon, Inc., today announced that effective February 5, 2010, Robert P. Roche, Jr.,Executive Vice President of Worldwide Pharmaceutical Operations, will resignhis position with the company to pursue other longstanding interests. Duringhis tenure, Mr.

FDA Extends Nuvigil Jet Lag Review by 3 Months

December 22, 2009 3:49 am | News | Comments

FRAZER, Pa. (AP) — The FDA needs more time to review Cephalon Inc.'s drug Nuvigil as a treatment for jet lag, Cephalon recently announced. Cephalon is seeking approval to market Nuvigil for the treatment of tiredness in jetlagged patients.

Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals

December 3, 2009 3:31 am | News | Comments

Cephalon, Inc. has filed a lawsuit in U.S. District Court in Delaware against Teva Pharmaceuticals USA, Inc. for infringement of U.S. Patent Nos.

Judges: Seattle Biotech Can Pursue $23M Claim Against Former Consultant

November 19, 2009 3:41 am | News | Comments

GENE JOHNSON Associated Press Writer SEATTLE (AP) — Seattle biotechnology firm Cell Therapeutics Inc. can pursue claims for nearly $23 million against a former consultant, a federal appeals court ruled Wednesday. The ruling by a three-judge panel of the 9th U.S.

Cephalon, Barr Settle Fentora Dispute

November 13, 2009 3:46 am | News | Comments

NEW YORK (AP) — Cephalon Inc. will give Barr Pharmaceuticals Inc. a license to sell a generic version of the pain drug Fentora in 2018 as part of a patent lawsuit settlement, according to a Securities and Exchange Commission filing Thursday.

Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation

October 26, 2009 5:26 am | News | Comments

Cephalon, Inc. and BioAssets Development Corporation, aprivately held biopharmaceutical company, today announced that the companieshave signed an agreement that will provide Cephalon with an option to acquireBDC.

FDA Grants Priority Review to Cephalon's sNDA for NUVIGIL as a Treatment for Excessive SleepinessAssociated with Jet Lag Disorder

September 24, 2009 5:05 am | News | Comments

Cephalon, Inc. has announced theFDA has granteda priority review for its supplemental New Drug Application (sNDA) forNUVIGIL(R) (armodafinil) Tablets 1/8C-IV3/8, which was filed in June of thisyear.

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.